Insmed Taps J&J Veteran Butera to Lead Respiratory Unit
Event summary
- Samuele Butera joins Insmed as SVP, General Manager of Global Respiratory on June 23, 2026.
- Butera brings over two decades of commercial leadership experience from J&J and Novartis.
- He will oversee the launch of BRINSUPRI, ARIKAYCE label expansion, and TPIP development program.
- Previously led multi-billion-dollar business units at J&J and global launches at Novartis.
The big picture
Insmed's appointment of Butera signals a strategic push to strengthen its respiratory franchise amid increasing competition. His experience in launching complex therapies and growing multi-billion-dollar businesses positions him to accelerate BRINSUPRI's commercialization and expand ARIKAYCE's market reach. The move underscores Insmed's focus on leveraging executive talent from industry giants to drive therapeutic innovation.
What we're watching
- Commercial Execution
- How Butera's track record at J&J will translate to Insmed's respiratory portfolio.
- Regulatory Momentum
- The pace of ARIKAYCE label expansion approvals and their impact on market positioning.
- Pipeline Progress
- Whether TPIP development can sustain Insmed's growth trajectory in respiratory therapeutics.